What Does ROIS's Phoenix Acquisition Mean for Injectable Manufacturing Capacity?

A state-of-the-art sterile injectable facility in Phoenix, Arizona, previously operated by Bristol Myers Squibb, has changed hands. ROIS — the contract development and manufacturing arm of ROVI — has completed the acquisition of the site, marking a significant structural shift in how the company positions itself to serve pharmaceutical development and manufacturing partners across the globe.

For drug developers evaluating manufacturing partners for sterile fill-finish programs, the practical implication is straightforward: US-based capacity from an established European injectable manufacturer is now available through a single network.¹ The Phoenix facility spans approximately 370,000 square feet and has received roughly $100 million in capital investment since 2021, leaving it well equipped for commercial-scale operations across vials, pre-filled syringes, and cartridges.

Of particular note for development teams working with oncology or other highly potent compounds, the site includes a cytotoxic and high-potent area rated to occupational exposure band 5, with commercial-scale lyophilization capability. The facility currently holds regulatory approvals from the FDA, the EMA, and Japanese authorities — a combination that matters when planning multi-market submissions or managing supply chains across regions.

How Does This Change the Competitive Landscape for Sterile Fill-Finish Outsourcing?

With this acquisition, ROIS brings its total global network capacity to over 800 million sterile units per year.¹ For pharmaceutical manufacturers and biotech companies planning long-term outsourcing strategies, that scale offers meaningful flexibility — particularly for programs that need to bridge European development with US commercial production without changing manufacturing partners mid-lifecycle.

Looking ahead, ROIS has announced plans to install an Optima pre-filled syringe isolator line within a segregated, non-potent area of the Phoenix site, targeted for 2027.¹ Once operational, that line is projected to add approximately 65 to 70 million pre-filled syringe units annually, addressing a segment of the market where capacity constraints have been a persistent challenge.

"This acquisition demonstrates where we are headed," said Kimberlee Steele, Chief Commercial Officer, RIOS, in a press release.¹ "We are establishing ROIS as a top 3 global CDMO for sterile fill-finish — growing, investing, and expanding capacity to meet our partners' needs worldwide."

The Phoenix site also extends ROIS's capability into antibody-drug conjugate fill-finish, an area where highly potent handling infrastructure and regulatory readiness are prerequisite to entry.¹ As ADC pipelines continue to expand across the industry, access to a certified, commercially scaled facility without the lead time of greenfield construction is a consideration worth tracking for any organization with an ADC program in development or approaching commercialization.

"This acquisition is a strategic step in building ROIS as a global CDMO for high-value injectables," Steele added, in the press release.¹ "The Phoenix site adds significant sterile fill-finish and high-potent capability, enabling us to better serve partners on US soil while continuing to invest across our network."

The move follows a broader period of repositioning for ROIS, which updated its branding in late 2025 alongside a series of senior talent appointments.¹ For prospective partners, what matters most is not the rebranding itself but what underpins it: continued capital deployment into infrastructure, regulatory-ready manufacturing capacity across two continents, and a stated focus on high-value, complex injectable modalities.

References

1. ROIS CDMO closes on the acquisition of US injectable manufacturing facility. ROIS CDMO. Published March 31, 2026. Accessed April 13, 2026. https://roiscdmo.com/rois-cdmo-closes-on-the-acquisition-of-us-injectable-manufacturing-facility/